Rachel Hildebrand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rachel Hildebrand has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Brittany J. Holmes
Department of Pathology, Stanford University, Stanford, California
52 shared publications - Christina S. Kong
Department of Pathology, Stanford University School of Medicine, Stanford, USA
52 shared publications - Dhanya K. Nambiar
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
52 shared publications - Hongbin Cao
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
52 shared publications - Li Guan
Department of Radiation Oncology, Stanford University School of Medicine, Stanford, California
52 shared publications - Quynh-Thu Le
Stanford University School of Medicine, Stanford, CA, USA
52 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells
Nrf2 mutation leads to extrinsic radiation resistance through recruitment of PMN-MDSC in tumors.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells
Nrf2 mutation leads to extrinsic radiation resistance through recruitment of PMN-MDSC in tumors.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
Sh-RNA knockdown sequences used in the study
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
Sh-RNA knockdown sequences used in the study
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Terminal Tumor volume of MOC2 WT/KO-Gal1 tumors in Rag2-/- IL2rg-/- mice. B. Gating strategy used for analyses of PMN-MDSCs and M-MDSCs in tumor and lung tissues. C. Unsupervised tSNE clustering of live cells in MOC2 WT/KO-Gal1 tumor showing the proportion of M-MDSC, PMN-MDSC, and CD8+ T cells. D. Visual representation of the spleens isolated from either naïve mice or mice bearing WT- or KO-Gal1 tumors. E. Comparison of MDSC enrichment scores between smaller T1-2 and larger T3-4 tumors in the HNSCC TCGA cohort. The student’s t-test was used to assess the significance of the difference between the two groups. F. Heat map showing gene expression clustering based on the MDSC enrichment score in the HNSCC TCGA cohort. Differentially expressed genes (DEGs) were defined by a false discovery rate smaller than 0.05 and fold change higher than 1.5. G. Representative images showing low and high staining Gal1 or LOX1 (OLR1, established marker of PMN-MDSCs) using immunohistochemistry (IHC). H. Table showing the distribution of tumors expressing high or low Gal1 and high or low LOX1 (PMN-MDSCs) in 81 patients with oral cavity tumors. Gal1 and LOX1 staining distribution was analyzed using a chi-square test and was not statistically significant.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Terminal Tumor volume of MOC2 WT/KO-Gal1 tumors in Rag2-/- IL2rg-/- mice. B. Gating strategy used for analyses of PMN-MDSCs and M-MDSCs in tumor and lung tissues. C. Unsupervised tSNE clustering of live cells in MOC2 WT/KO-Gal1 tumor showing the proportion of M-MDSC, PMN-MDSC, and CD8+ T cells. D. Visual representation of the spleens isolated from either naïve mice or mice bearing WT- or KO-Gal1 tumors. E. Comparison of MDSC enrichment scores between smaller T1-2 and larger T3-4 tumors in the HNSCC TCGA cohort. The student’s t-test was used to assess the significance of the difference between the two groups. F. Heat map showing gene expression clustering based on the MDSC enrichment score in the HNSCC TCGA cohort. Differentially expressed genes (DEGs) were defined by a false discovery rate smaller than 0.05 and fold change higher than 1.5. G. Representative images showing low and high staining Gal1 or LOX1 (OLR1, established marker of PMN-MDSCs) using immunohistochemistry (IHC). H. Table showing the distribution of tumors expressing high or low Gal1 and high or low LOX1 (PMN-MDSCs) in 81 patients with oral cavity tumors. Gal1 and LOX1 staining distribution was analyzed using a chi-square test and was not statistically significant.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
Immunoblot showing knockdown of STING in MOC2 WT/KO cells.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
Immunoblot showing knockdown of STING in MOC2 WT/KO cells.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Quantification of PMN-MDSCs (CD11b+Ly6Clo/intLy6G+) in the liver and kidneys of MOC2 WT- or KO-Gal1 tumor-bearing mice at matched tumor volumes in comparison with naïve mice. B. Gating strategy used to quantify Arginase (Arg1) and interleukin-10 (IL-10) expression on PMN-MDSCs isolated from the tumor or the lungs of naïve mice or mice with pre-metastatic niches (sub-gated on CD45+ live cells). C. Heat map showing differential gene expression from PMN-MDSCs isolated from tumor and lung tissues of MOC2 WT-Gal1 tumor-bearing mice compared with naïve neutrophils. D. STRING analysis showing two clusters of genes representing IL-17 and collagen synthesis pathways that are upregulated PMN-MDSCs isolated from pre-metastatic lung tissues. E. Reactome pathway enrichment analyses performed using RNA-SEQ data showing pathway represented by upregulated genes in PMN-MDSCs isolated from pre-metastatic lung tissues. F. Quantification of Trichrome staining intensity in mEERL WT- or KO-Gal1 tumor-bearing mice lungs, n=5/group. G. tSNE plot showing depletion of PMN-MDSCs in the blood following injection of anti-GR1 antibody in mice compared with isotype alone.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Quantification of PMN-MDSCs (CD11b+Ly6Clo/intLy6G+) in the liver and kidneys of MOC2 WT- or KO-Gal1 tumor-bearing mice at matched tumor volumes in comparison with naïve mice. B. Gating strategy used to quantify Arginase (Arg1) and interleukin-10 (IL-10) expression on PMN-MDSCs isolated from the tumor or the lungs of naïve mice or mice with pre-metastatic niches (sub-gated on CD45+ live cells). C. Heat map showing differential gene expression from PMN-MDSCs isolated from tumor and lung tissues of MOC2 WT-Gal1 tumor-bearing mice compared with naïve neutrophils. D. STRING analysis showing two clusters of genes representing IL-17 and collagen synthesis pathways that are upregulated PMN-MDSCs isolated from pre-metastatic lung tissues. E. Reactome pathway enrichment analyses performed using RNA-SEQ data showing pathway represented by upregulated genes in PMN-MDSCs isolated from pre-metastatic lung tissues. F. Quantification of Trichrome staining intensity in mEERL WT- or KO-Gal1 tumor-bearing mice lungs, n=5/group. G. tSNE plot showing depletion of PMN-MDSCs in the blood following injection of anti-GR1 antibody in mice compared with isotype alone.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 6 from NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells
CB-839 overcomes RT resistance in Nrf2E79Q MOC1 cells through regulating the tumor microenvironment.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 6 from NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells
CB-839 overcomes RT resistance in Nrf2E79Q MOC1 cells through regulating the tumor microenvironment.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Gating strategy for CD8+ T cells in the spleen of mice treated with either MOC2 WT/KO-Gal1 CM. B. Quantitation of PMN-MDSCs and T cells in the spleen of mice bearing KO-Gal1 tumors injected with either WT- or KO-Gal1 CM for 3 weeks. C. Graph showing the 48-plex mouse cytokine Luminex assay results performed on the 10x concentrated condition media from MOC2 WT/KO-Gal1 tumor cells. The media was collected in 3 independent experiments and run as a single batch. D. Gating strategy for CXCR2 staining on PMN-MDSCs isolated from the tumor and pre-metastatic lungs.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Gating strategy for CD8+ T cells in the spleen of mice treated with either MOC2 WT/KO-Gal1 CM. B. Quantitation of PMN-MDSCs and T cells in the spleen of mice bearing KO-Gal1 tumors injected with either WT- or KO-Gal1 CM for 3 weeks. C. Graph showing the 48-plex mouse cytokine Luminex assay results performed on the 10x concentrated condition media from MOC2 WT/KO-Gal1 tumor cells. The media was collected in 3 independent experiments and run as a single batch. D. Gating strategy for CXCR2 staining on PMN-MDSCs isolated from the tumor and pre-metastatic lungs.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 2 from NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells
The relationship between NFE2L2 mutation and radiation resistance in OC cancer. Kaplan-Meier analysis of PFS and OSin OC patients treated with surgery and postoperative (chemo)radiotherapy.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 2 from NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells
The relationship between NFE2L2 mutation and radiation resistance in OC cancer. Kaplan-Meier analysis of PFS and OSin OC patients treated with surgery and postoperative (chemo)radiotherapy.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Quantification of phospho-p65 (NF-kb) staining in MOC2 and mEERL WT/KO-Gal1 tumors (N=5 tumors, 3 random microscopic fields per tumor). B. Quantitation of STING mRNA levels in MOC2 and mEERL WT/KO-Gal1 cell lines. C. Immunoblot showing degradation kinetics of STING in LLC and FaDU WT/KD-Gal1 cells at 1, 2, 4h post cycloheximide treatment. D. Magnified images showing co-localization of STING and LAMP1 in MOC2 WT/KO-Gal1 cells. E. Representative images showing low and high IHC staining of STING in oral cavity cancer (Left) and the distribution of negative and positive STING staining in 83 oral cavity cancers on the TMA. F. Kaplan Meier curve showing progression-free survival (calculated as the time from the surgery date until death or progression) of patients based on Gal1 and STING expression in the tumor.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Galectin-1 Mediates Chronic STING Activation in Tumors to Promote Metastasis through MDSC Recruitment
A. Quantification of phospho-p65 (NF-kb) staining in MOC2 and mEERL WT/KO-Gal1 tumors (N=5 tumors, 3 random microscopic fields per tumor). B. Quantitation of STING mRNA levels in MOC2 and mEERL WT/KO-Gal1 cell lines. C. Immunoblot showing degradation kinetics of STING in LLC and FaDU WT/KD-Gal1 cells at 1, 2, 4h post cycloheximide treatment. D. Magnified images showing co-localization of STING and LAMP1 in MOC2 WT/KO-Gal1 cells. E. Representative images showing low and high IHC staining of STING in oral cavity cancer (Left) and the distribution of negative and positive STING staining in 83 oral cavity cancers on the TMA. F. Kaplan Meier curve showing progression-free survival (calculated as the time from the surgery date until death or progression) of patients based on Gal1 and STING expression in the tumor.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplemental Tables from NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells
Supplemental Table 1 shows patients distribution in OC cohorts from Stanford University. Supplemental Table 2 shows primers for mutagenesis. Supplemental Table 3 shows primers for real-time PCR. Supplemental Table 4 shows gene mutations identified by targeted next generation sequencing in a cohort of oral cavity cancer patients treated with surgery and postoperative (chemo)radiotherapy at Stanford University. Supplemental Table 5 shows tumor growth delay of indicated MOC1 xenografts using 1000mm3 tumor size as a proxy.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Tables from NFE2L2 Mutations Enhance Radioresistance in Head and Neck Cancer by Modulating Intratumoral Myeloid Cells
Supplemental Table 1 shows patients distribution in OC cohorts from Stanford University. Supplemental Table 2 shows primers for mutagenesis. Supplemental Table 3 shows primers for real-time PCR. Supplemental Table 4 shows gene mutations identified by targeted next generation sequencing in a cohort of oral cavity cancer patients treated with surgery and postoperative (chemo)radiotherapy at Stanford University. Supplemental Table 5 shows tumor growth delay of indicated MOC1 xenografts using 1000mm3 tumor size as a proxy.